Natalia Montiel

Natalia Montiel

Auto-generated profile, based on publicly available information

Natalia Montiel

Hospital Costa del Sol

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2015 in BioMed Research International
Verified
Journal Article
Open access
PDF file
MMMaría Concepción Mediavilla-Gradolph
María Concepción Mediavilla-Gradolph
ITInmaculada De Toro-Peinado
Inmaculada De Toro-Peinado
MBMaría Pilar Bermúdez-Ruiz
María Pilar Bermúdez-Ruiz
MGMaría de Los Ángeles García-Martínez
María de Los Ángeles García-Martínez
MOMaría Ortega-Torres
María Ortega-Torres
BPBegoña Palop-Borrás
Begoña Palop-Borrás
The aim of this study was to compare the results obtained for identification by MALDI-TOF of nontuberculous mycobacteria (NTM) isolated in clinical samples with those obtained by GenoTypeMycobacteriumCM/AS (common mycobacteria/additional species). A total of 66Mycobacteriumisolates from various clinical specimens (mainly respiratory) were tested in this study. They were identified using MALDI-TOF Bruker from strains isolated in Lowenstein, following the recommended protocol of heat inactivation and extraction, and were simultaneously analyzed through hybridization by GenoTypeMycobacteriumfrom liquid culture MGIT. Our results showed that identification by MALDI-TOF was correct in 98.4% (65/66) of NTM isolated in our clinical practice (M. avium, M. intracellulare, M. abscessus, M. chelonae, M. fortuitum, M. mucogenicum, M. kansasii, and M. scrofulaceum). MALDI-TOF was found to be an accurate, rapid, and cost-effective system for identification of mycobacteria species.

1 August 2016 in Journal of Clinical Virology
Verified
Journal Article
Open access
VKVladimir Kartashev
Vladimir Kartashev
MDMatthias Döring
Matthias Döring
LNLeonardo Nieto
Leonardo Nieto
ECEleda Coletta
Eleda Coletta
RKRolf Kaiser
Rolf Kaiser
THT. Haque
T. Haque
HCV affects 185 million people worldwide and leads to death and morbidities. HCV has a high genetic diversity and is classified into seven genotypes and 67 subtypes. Novel anti-HCV drugs (Direct-Acting-Antivirals) eligibility, resistance and cure rates depend on HCV geno/subtype (GT). Analysis of epidemiological information and viral GT from patients undergoing viral genotyping in 2011-2015. Anonymized information from 52 centers was analyzed retrospectively. 37,839 samples were included in the study. We show that the GT distribution is similar throughout Western European countries, with some local differences. Here GTs 1 and 2 prevalences are lower and of GT4 higher than in all previous reports. Israel has a unique GT pattern and in South Russia the GT proportions are more similar to Asia. GTs 5 and 6 were detected in very low proportions. Three cases of the recombinant genotype P were reported in Munich (Germany). In addition, we observed that GT proportion was dependant on patientś gender, age and transmission route: GTs 1b and 2 were significantly more common in female, older, nosocomially-infected patients, while GTs 1a, 3 and 4 were more frequent in male, younger patients infected by tattooing, drug consume, and/or sexual practices. In infections acquired by drug consume, GTs 1a (35.0%) and 3 (28.1%) prevailed. In infections related to sexual practices lower proportion of GT3 (14.0%) and higher of GT4 (20.2%) were detected. GT4 was mostly abundant in MSM (29.6%). HIV coinfection was significantly associated with higher proportions GTs 1a and 4 (42.5% and 19.3%, respectively). Genotype prevalence evolves and correlates to epidemiological factors. Continuous surveillance is necessary to better assess hepatitis C infection in Europe and to take appropriate actions.

27 December 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AAAdela Alcolea-Medina
Adela Alcolea-Medina
MFM. T. Cabezas Fernandez
M. T. Cabezas Fernandez
NMN. Montiel
N. Montiel
MGM. P. Luzón García
M. P. Luzón García
CSC. Delamo Sevilla
C. Delamo Sevilla
MWMark Wilks
Mark Wilks
The aim of this study was to establish a simple method for the rapid identification of Mycobacteria species by MALDI-TOF (Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass spectrometry) using the Bruker MALDI-TOF Biotyper system (Bruker Daltonik, Bremen, Germany). A multicentre, prospective, and single blind study was performed in three European Hospitals, two Spanish and one UK hospital from May to August 2018. The BD BACTEC MGIT (Becton Dickinson, Berks, UK) liquid culture system was used in all three centres for the growth of Mycobacteria. When signal positive, tubes were removed from the analyser and in addition to standard laboratory procedures were subcultured on blood agar plates for MALDI-TOF analysis. Plates were incubated aerobically for 1 to 7 days at 37 °C and inspected every day. Once any growth was visible, it was transferred to the steel target plate, overlaid with 1 μl of neat formic acid and 1 μl HCCA matrix (alpha hydroxyl 4 cinnamic acid), and analysed in a Bruker Biotyper MALDI-TOF. Results given by MALDI-TOF were compared with the reference methods used for identification in the different centres. At two Spanish hospitals, identification by MALDI-TOF was only attempted on presumptive non-tuberculosis mycobacteria (NTM) and the results were initially compared with the results obtained by a commercial reverse hybridisation assay, GenoType CM/AS (Hain Lifescience, Tübingen, Germany). At the UK Hospital, identification of any presumptive mycobacteria was attempted and compared with the results obtained by whole genome sequencing (WGS). Overall in 142/167 (85%) of cases the identifications obtained were concordant; all Mycobacterium tuberculosis (MTB) isolates 43/43 (100%), 57/76 (75%) of the rapid growing nontuberculous mycobacteria (NTM), and 42/48 (85%) slow growing NTM tested were identified correctly. We report a new, easy, cheap and quick method for isolation and identification of Mycobacterium spp. without the need for additional steps or equipment and this method is in routine used in all three centres.

14 December 2010 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
OCOscar Cuevas
Oscar Cuevas
JOJesús Oteo-Iglesias
Jesús Oteo-Iglesias
ELEdurne Lázaro
Edurne Lázaro
BABelén Aracil
Belén Aracil
Francisco J. De AbajoFrancisco J. De Abajo
Francisco J. De Abajo
VGV. Gallardo
V. Gallardo
To determine trends in ciprofloxacin resistance and co-resistance to other antibiotic classes in blood isolates of Escherichia coli, and to investigate if there is an ecological relationship to the community use of fluoroquinolones and other antibiotics. Forty-two Spanish hospitals of the European Antimicrobial Resistance Surveillance Network collected ciprofloxacin and other antibiotic susceptibility data for non-duplicate consecutive E. coli isolates from patients with bacteraemia between 2001 and 2009. The nationwide ambulatory use of antibiotics between 1997 and 2008 was determined by WHO methods, and the co-evolution of both parameters was further analysed. Of the 28 307 E. coli blood isolates, 27.9% were ciprofloxacin non-susceptible (CIPNS), increasing from 17.6% in 2001 to 32.7% in 2009. A continuous increase was observed between CIPNS and other resistances, including cephalosporin resistance due to the production of extended-spectrum β-lactamases (ESBLs) and non-susceptibility to both amoxicillin/clavulanic acid and tobramycin. Although the total use of antibiotics did not increase, community use of levofloxacin, moxifloxacin and amoxicillin/clavulanic acid increased by 307.2%, 62.6% and 70.1%, respectively. Yearly rates of CIPNS E. coli strongly correlated with the use of levofloxacin, moxifloxacin and amoxicillin/clavulanic acid (r2 > 0.80; P < 0.005 in all cases). The rapid increase in CIPNS E. coli causing bacteraemia was closely related to the increase in resistance to amoxicillin/clavulanic acid, production of ESBLs and resistance to aminoglycosides. Community use of fluoroquinolones (mainly moxifloxacin and levofloxacin) and of amoxicillin/clavulanic acid represents a significant driver in the progression of fluoroquinolone resistance in bacteraemic E. coli.

30 July 2015 in Digestion
Verified
Journal Article
Closed access
JNJosé María Navarro-Jarabo
José María Navarro-Jarabo
FFFernando Fernández-Sánchez
Fernando Fernández-Sánchez
NFNuria Fernández-Moreno
Nuria Fernández-Moreno
AHAntonio José Hervas-Molina
Antonio José Hervas-Molina
FCFrancisco Casado-Caballero
Francisco Casado-Caballero
NQNatalia Montiel Quezel-Guerraz
Natalia Montiel Quezel-Guerraz
Background: The eradication of Helicobacter pylori (HP) using clarithromycin (CLA)-based triple therapy depends on the resistance of HP to antibiotics. The Maastricht III conference recommends the implementation of locoregional surveillance programmes for primary resistance of HP to CLA. In Andalusia, there are no previous data in this respect. The aim of this study was to determine the prevalence of the primary resistance of HP to CLA and levofloxacin (LF) in southern Spain. Methods: Multicentre cross sectional study was carried out in 6 hospitals in Andalusia. Patients of both sexes numbering 401 were included (male 48%), aged 18-80 years and naïve to HP eradication. Resistance of HP to CLA (CLAr) and LF (LFr) was assessed by determining mutations by PCR: mutations of the 23S rRNA gene define CLAr and mutations of the gene gyrA define LFr. Four hundred one gastric samples were collected. CLAr was detected in 72 patients (17.9%) and LFr was detected in 56 patients (13.9%). Heteroresistance was detected for both antibiotics: CLA 37/72 (51.3%) and LF 28/56 (50%). Variability for CLAr was detected among the centres, ranging from 11.5% to 24.7% without statistical significance (p = 0.12). Female sex was related to CLAr. Conclusions: In Andalusia, there is a high rate of primary CLAr and LFr. CLA-based triple therapy should be avoided as the primary eradication regimen in this region. There is a wide variability in the rate of CLAr among centres.

1 March 2017 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
AAA. Aguilera
A. Aguilera
DND. Navarro
D. Navarro
FRFrancisco Rodríguez-Frías
Francisco Rodríguez-Frías
IVI. Viciana
I. Viciana
AMA. M. Martínez‐Sapiña
A. M. Martínez‐Sapiña
FGFederico Garcia
Federico Garcia